Clinical Trials List
2025-04-01 - 2035-12-31
Phase II
Recruiting3
ICD-10C50.911
Malignant neoplasm of unspecified site of right female breast
ICD-10C50.912
Malignant neoplasm of unspecified site of left female breast
ICD-10C50.919
Malignant neoplasm of unspecified site of unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.9
Malignant neoplasm of female breast, unspecified
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/06/01
Investigators and Locations
Co-Principal Investigator
- 楊舜如 Division of General Surgery
- 黃怡璇 Division of General Surgery
- Shang-Hung Chen Division of General Surgery
- Jui-Hung Tsai Division of General Surgery
- Chun-Hui Lee Division of General Surgery
- 黃怡菁 Division of General Surgery
- Zhu-Jun Loh Division of General Surgery
- 陳慧雯 Division of General Surgery
- Wei-Pang Chung Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- HSIN-CHEN LIN Division of General Surgery
- 楊捷儒 Division of General Surgery
- Chi-Long Chen Division of General Surgery
- 王國鐘 Division of General Surgery
- 林慈恩 Division of General Surgery
- 楊陽生 Division of General Surgery
- ZHENG-WEI ZHOU Division of General Surgery
- Huey-En Tzeng Division of General Surgery
- I-Chen Tsai Division of General Surgery
- Kuan-Der Lee Division of General Surgery
- 劉佳樺 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
17 participants
-
Global
372 participants
